Revolutionizing cancer treatment, immune checkpoint inhibitors (ICIs) have nonetheless encountered a challenge: a substantial portion of gastric cancer (GC) patients don’t respond to this therapy. This pressing issue necessitates a deeper understanding of the resistance mechanisms against ICIs and t...
ORGANISM(S): Homo Sapiens